Merck’s PREVYMIS effective for prevention of cytomegalovirus disease in adults post kidney transplantation
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint